|
Stable and soluble antibodies inhibiting tnfα Invention relates to biochemistry, particularly to an antibody or a fragment of said antibody, which specifically binds with human TNFα, wherein the antibody or antibody fragment contains a human heavy chain framework region sequence and a CDR sequence, derived from a rabbit antibody, as well as to a composition for treating TNFα-mediated diseases, which contains said antibody or fragment. The invention also discloses isolated nucleic acid which codes a heavy chain variable region and a light chain variable region of said antibody or fragment thereof, as well as an expression vector containing the same, and a host cell containing said vector. The invention also discloses use of said antibody or antibody fragment to obtain a medicinal agent for treating or preventing a human TNFα-mediated disease, as well as use in a method of treating or preventing a TNFα-mediated disease. |
|
Composition of antiperspirant/deodorant Invention provides an antiperspirant composition in the form of a stick, comprising: a) an antiperspirant active substance; b) more than 15 wt % vegetable oil; c) less than 40 wt % volatile silicone oil; d) gel-forming substance comprising hydrogenated soybean oil and fatty alcohol. |
|
Composition, accelerating adiponectin production Invention relates to pharmaceutical industry, namely to composition, accelerating adiponectin production and possessing promoter activity with respect to adiponectin production. Composition, contributing to adiponectin production and possessing promoter activity with respect to adiponectin production, contains extracts of salmon milt, brewer's yeast, avian collagen and mineralised yeasts, characterised by certain composition. |
|
Liquid cleaning compositions, containing long-chain fatty alcohols Invention relates to field of cosmetic industry. Invention represents composition, which includes: a) surface-active substance, which includes anionic surfactant, b) at least 8 wt % of composition of C12-18 fatty alcohol, and c) water and cleaning method, including application of composition on skin or hair, and optional rinsing with water. |
|
Method for producing antiseptic stimulator for treating farm animals Invention represents a method for producing an antiseptic stimulator, wherein a raw product is antiseptic stimulator D-3 fraction produced by dry distillation of organic substances, e.g. meat and bone meal with the fat weight ratio from 10 to 20%, the water weight ratio up to 9%, the ash weight ratio up to 26%, the cellulose weight ratio up to 2%; the substances are thermally treated for 12 hours at temperature from 200 to 550°C; volatile fractions are condensed by cooling and settled until split to two fractions with fraction 3 to be separated and packed as spray into aerosol tin, aluminium and plastic cans of 10-1000 ml with a sprayer cap and a pipe up to 50 cm long. |
|
|
Disclosed is ibuprofene chewing tablet of direct pressing with masked taste. Ibuprofene chewing tablet contains therapeutically effective quantity of ibuprofene and pharmaceutically acceptable carrier, where ibuprofene has the average size of particles from 250 mcm to 400 mcm. |
|
|
Invention relates to field of medicine and represents coating for medical device, inhibiting aggressive form of healing, which contains, at least, one nitrocarboxylic acid. |
|
Group of inventions relates to teeth-cleaning preparations, which contain Himalayan salt and/or Sango corals, with Himalayan salt being used directly in form of natural raw material. Preparations also contain silica, chalk and/or sodium bicarbonate, glycerol, and/or sorbitol, and/or xylitol and/or mannite, xanthan and alginate, extracts of different herbs and water in specified quantities. Thus, versions of preparation, made in form of dental cream, contain extracts of horsetail, melia and myrrh with addition of extracts of sage, rosemary, tea-tree and thyme or cloves, fennel, cinnamon and Echinacea or mint and mint subspecies, eucalyptus, chamomile and sage. Version of preparation, made in form of dental gel, contains Sango corals an, additionally, zeolite and quartz in combination with extracts of horsetail, melia, Echinacea, sage, myrrh, anise, curly mint and lemon, with saline of Himalayan salt being used in gel composition instead of water. |
|
|
Inhibitors of cell cycle checkpoint kinase 1 for amplification of dna-damaging agents Claimed is application of inhibitor of cell cycle checkpoint kinase 1 (CHK1), representing some derivatives of N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrole[2,3-b]pyridine-3-yl), or N-(5-bromo-4-(3-(methylamino)piperidin-1-yl)-5-bromo-1H-pyrrole[2,3-b]pyridine-3-yl)nicotinamide, for amplification of DNA-damaging agent, with first dose of said inhibitor being introduced 1 day after DNA-damaging agent, and second dose - two days after DNA-damaging agent. |
|
Solution for peritoneal dialysis Intracorporeal detoxification preferentially conducted in a clinical setting involves using a solution containing albumin, Fraxiparine, dialysis fluid. The solution additionally contains papaverine, platyphyllin and heparine in the following proportions, wt %: albumin - 3-5%, Fraxiparine - 0.025-0.075%, papaverine - 0.3-0.6%, platyphyllin - 0.015-0.03%, heparin - 0.025-0.05%, dialysis fluid - the rest. |
|
|
Group of inventions relates to the application of a hydrocortisone derivative of formula (I) |
|
Aerosol formulation for treating chronic obstructive pulmonary disease Invention refers to pharmaceutics. A pharmaceutical aerosol composition in the form of a solution for an aerosol metered-dose inhaler is described. The composition contains glycopyrronium chloride dissolved in HFA propellant, and a co-solvent representing ethanol. The invention also refers to using the above composition for producing a medicinal product and to a method for aerosol container charge with the above composition. |
|
|
Preparation for skin care, possessing antifungal properties (versions) Invention represents preparation for skin care, possessing antifungal properties and contains hydrochloride of 2-benzimidazolylcarbamic acid methyl ether, salicylic acid, dimethylsulphoxide and ethanol, with components in preparation being in specified ratio in wt %. |
|
Echinacea tincture and method for producing echinacea tincture Invention refers to chemical-pharmaceutical industry, namely to Echinacea herb tincture having immunomodulating, immunopotentiating, antimicrobial, anti-inflammatory, antiviral activity and a method for producing it. The method for producing Echinacea herb tincture consists in extracting ground Echinacea herb in ethanol, infusing, then mixing, infusing more, pouring off a portion of the extract; after pouring off the extract, the process herb is added with fresh extracting agent, infusing while stirring at regular intervals; all the extract is poured off; the prepared extracts are combined and cooled thoroughly, filtered in a certain environment. Using the method for producing the Echinacea herb tincture having immunomodulating, immunopotentiating, antimicrobial, anti-inflammatory and antiviral activity. The Echinacea herb tincture having immunomodulating, immunopotentiating, antimicrobial, anti-inflammatory and antiviral activity. |
|
|
Per orally decomposing tablet compositions, containing combinations of non-opiate analgesics Claimed group of inventions, which includes a pharmaceutical composition, a method of its obtaining, a drug form for per oral introduction with the claimed composition and a method of obtaining the drug form. The claimed invention is aimed at the pharmaceutical composition of a non-opiate analgesic/opiate analgesic, in which the non-opiate analgesic is contained in the core, opiate - in the first core coating, there is the second core coating with a water-insoluble polymer, as well as the second set of particles, containing the non-opiate analgesic and its coating with the water-insoluble polymer. |
|
Method of treating acute secondary pyelonephritis Treating acute secondary pyelonephritis is ensured by prescribing Enterosgel 20 g three times a day before meals during 2 weeks with underlying immune-enhancing and anti-inflammatory therapy. |
|
Lactococcus lactis strain for treatment or prevention of digestion disorder and thereof application Group of inventions relates to strain Lactococcus lactis CNCM I-2807, intended for treatment or prevention of digestion disorder, and its application. Strain Lactococcus lactis CNCM I-1631 can also be applied for treatment or prevention of digestion disorder. Diameters of zones of inhibiting pathogenic organisms E. coli, L. monocytogenes and S. enteritidis in incubation with strain Lactococcus lactis CNCM I-1631 constitute more than 6 mm. After 4 hours of incubation with apical part of monolayer of T84 cells value of transepithelial electric resistance constitutes 108.54% for strain Lactococcus lactis CNCM I-2807 and 110.90% for strain Lactococcus lactis CNCM I-1631. |
|
New version of alpha-1-antitrypsin, method of its production and application Invention relates to the field of biotechnology, specifically to production of version of alpha-1-antitrypsin, and can be used in medicine for prevention or treatment of deficiency of alpha-1-antitrypsin. The version of alpha-1-antitrypsin is obtained by replacement of amino acid in 4, 9 or 12 position of N-terminus of alpha-1-antitrypsin on asparagine for the purpose of adding the glycosylation site. |
|
Invention relates to biochemistry. Method includes determination of level of polypeptide with said sequence in plasma by means of antigen, where Thr90 of polypeptide is phosphorylated. Also diagnostic sets for detection of presence of tumour metastases are described, for screening for presence of tumour among high risk population, for determination of prognosis for patient, for determination of efficiency of surgery, radiotherapy or chemical therapy with respect to patient with tumour, and/or determination of the time when treatment must be stopped. Diagnostic sets include polypeptide with sequence, given in materials, where Thr90 of polypeptide is phosphorylated. |
|
Invention relates to field of biotechnology and can be applied for regeneration of tissues of mesodermal origin with application of adult organism fibroblasts. Sampling of skin tissues is carried out, obtained bioptate is washed in physiological solution with human albumin, after which it is processed with solution of dispase in culture medium DMEM-LG with glucose content 1 g/l until epidermis is separated from derma. Obtained derma is washed with DMEM-LG and mechanically crushed, derma fragments are distributed around Petri dish and poured with DMEM-LG with foetal bovine serum (FBS), solution of non-essential amino acids (MEM NEAA) and antibiotics. After that, cells are cultivated until fibroblasts fill the entire bottom surface of dish, then they are removed with enzyme, washed, filtered and precipitated by centrifugation. Cell sediment is suspended in growth medium and cultured in flasks in CO2-incubator until confluent monolayer is obtained, after which cells are removed with enzyme, precipitated and passaged until required therapeutic quantity. Obtained fibroblasts are used for manufacturing transplants for human tissue regeneration. |
|
Meningococcal fhbp polypeptides Invention refers to biochemistry, particularly to a polypeptide containing the amino acid sequence SEQ ID NO: 20 eliciting a mammalian immune response to meningococcal bacteria. What is presented is a nucleic acid coding the above polypeptide. There are presented a plasmid containing the above nucleotide sequence, and a host cell transformed by the above plasmid; both plasmid, and host cell are applicable for expression of this polypeptide. What is presented is a membrane vesicle comprising the above polypeptide applicable as a medicinal product for preventing meningococcal infection in a mammal. What is disclosed is an immunogenic composition containing an effective amount of the polypeptide or vesicle. |
|
Method of production of biomass containing plantaricyne and its use for medical purposes Strain of lactobacillus Lactobacillus plantarum DSM 23213 and strain of lactobacillus Lactobacillus rossiae DSM 23214 are suggested, their joint cultivation activates synthesis of plantaricyne A, K and N and production of the product containing plantaricyne A, K and N. Product is produced by cultivation of the said strains, co-inoculation by water suspension of substrate lactobacillus, incubation at 30-37°C, preferably 30°C for 18-24 h, preferable 18 h. Said suspension has cell density about 9.0 log CFU/ml for each type of lactobacillus, and is added to the substrate in percentage ratio to volume of substrate from 1 to 4%. The produced product is used as part of pharmaceutical and cosmetic compositions, and during manufacturing of the medicament to increase barrier function of the epidermis or intestine, or for wound repair. |
|
Food components delivery system Proposed invention relates to food industry, in particular, to manufacture of taste-and-flavour compounds delivery systems. The delivery system has a structure containing surfactant aggregates; the delivery system contains a surfactant system chosen from the group consisting of non-ionic and zwitterionic surfactants (such surfactant contained in an amount equal to and exceeding its critical micelle formation concentration), a hydrophilic phase represented by water and/or water solvent in an amount of 10 wt % or more relative to the total weight of delivery system and 00001 - 5 wt % relative to the total weight of the system for delivery of the compound with the structure |
|
Method of treating hyperlipidemia Performed are sessions of a needle therapy covering corporeal biologically active points of acupuncture E 36, GI 4, RP 6, GI 11, E 39, F 3, RP 10, MC 6, C 5. One 21-day therapeutic course involves 10 sessions of the needle therapy covering the corporeal biologically active points from both sides. At the same time, microneedles are inserted for 21 days into auricular points from both sides. That involves the auricular points Shen-Men (55), Hypotensive (59), Adenohypophysis and Adrenal Cortex (13), Liver (97), Stomach (87), Brain's Hunger Centre (18), Cardial (86). Besides, from the second therapeutic day, the homeopathic medicine "Hepar Compositum" is injected intramuscularly during 10 days every second day. The treatment involves 2-3 therapeutic courses every 30 days. To the period of the treatment, the patient is recommended to keep a diet and correct a body weight. |
|
|
In formula 1 X represents N or CR, and Y represents N or CH on condition that X and Y are not simultaneously carbon; Z represents N or CH; R1 and R2 represent independently hydrogen, (C3-C10)cycloalkyl, norbornyl, adamantyl or noradamantyl, or R1 and R2 can be bound with each other together with nitrogen atoms, to which they are bound, with the formation of (C5-C10) saturated or unsaturated heterocycle or condensed heterocycle, on condition that R1 and R2 are not simultaneously hydrogen; L represents a single bond, -CO-, -SO2-, -(CR21R22)-(CH2)c- (c represents an integer number 0-5), , -CO(CR21R22)d- (d represents an integer number 1-6), (C3-C10)cycloalkylene, (C6-C20)arylene or 5-6-membered heteroarylene, including one or two heteroatoms, selected from N; R21 and R22 represent independently hydrogen or (C1-C10)alkyl, R represents hydrogen or hydroxyl; R4 and R5 independently represent hydrogen or (C1-C10)alkyl, or R4 and R5, bound together form a 6-membered unsaturated carbocycle; R6 and R7 represent independently hydrogen, (C1-C10)alkyl or halogen; R31-R38, R41-R43 and R46 represent independently hydrogen or (C1-C10)alkyl; and m and n independently represent an integer number 0-3 on condition that m+n represent an integer number 2 or larger. Values of radical R3 and additional substituents of cyclic groups R1-R3, L are given in the invention formula. The invention also relates to pharmaceutical composition, containing the said compounds, and to the 11β-HSD1 inhibitor. |
|
Claimed invention relates to peroxide compounds of formula |
|
Modulator of nmda-receptor with stabilised secondary structure and its usage Invention refers to compounds possessing high activity targeted on modulating NMDA-receptor activity and using the same for treating diseases and disorders, such as learning disorder, cognitive disorders and analgesia, and particularly for relieving and/or eliminating neuropathic pain. |
|
Invention relates to novel 1,3-dioxoindene derivatives of structural formula 1 which can be applied for prevention or treatment of viral disease, caused by picornavirus. In formula 1 A1, A2, A3 and A4 is independently selected from the group, consisting of -H, C1-C10alkoxy, -NO2, -NR1R2 and -NR1(C=O)R2, where A4 does not exist, when Z3 represents nitrogen, and at least one of A1-A4 is not hydrogen; G represents -OH, -N3, C1-C10alkoxy, -O(C=O)R1, -O(C=O)OR1, -O(C=O)NR1R2, -NR1R2, -NR1(C=O)R2, -NR1(C=O)OR2, -NR1(C=O)-NR2R3, or D1, D2, D3 and D4 is independently selected from the group, consisting of -H, halogen, -OH, C1-C10alkoxy, C1-C10 linear alkyl or alkyl with side chain, C6aryl, - (CH2)n-(C=O)OR1, -O(C=O)R1, -(C=O)R1, -NO2, -NR1(C=O)R2 and -SR1, or substituents D2 and D3 together can form six-membered ring, where ring, formed by substituents D2 and D3, can include one or several heteroatoms, and heteroatom represents N, and where D4 does not exist, when Z1 represents nitrogen, and D2 does not exist, when Z2 represents nitrogen; E represents -H, -OH, -OR1, -O(C=O)R1, -O(C=O)OR1, -O(C=O)NR1R2, -NR1(C=O)R2 or -SR1; each R1, R2 and R3 independently represents hydrogen, non-substituted or phenyl-substituted C1-C10 linear alkyl or alkyl with side chain, C1-C10alkoxy, non-substituted or phenyl-substituted C1-C10 linear alkenyl or alkenyl with side chain, C3cycoalkyl or non-substituted C6aryl; each X and Y independently represents hydrogen or oxygen; Z1, Z2 and Z3 represent carbon or nitrogen; n is equal to integer number from 1 to 10; and stands for single or double bond. Invention also relates to method of obtaining claimed compounds and to pharmaceutical composition, which contains claimed compound. |
![Aryl-cyclohexyl-tetraazabenzo[e]azulenes](http://img.russianpatents.com/img_data/1223/12237553-s.jpg)
|
Aryl-cyclohexyl-tetraazabenzo[e]azulenes Invention relates to compounds of formula I and their pharmaceutically acceptable salts. In formula I R1 is selected from the group, consisting of H; -C1-6-alkyl, non-substituted or substituted with 1 group OH; -(CH2)p-R4, p is equal 0 or 1, R4 represents 6-membered heteroaryl, containing 1 heteroatom of N; -S(O)2-C1-6-alkyl; -C(O)-C1-6-alkyl; and -C(O)O-C1-6-alkyl; R2 is selected from the group, consisting of hydrogen and halogen; R3 represents C6-10-aryl, non-substituted or substituted with 1-2 substituents, individually selected from the group, consisting of halogen, cyano, C1-6-alkyl, C1-6-alkoxy, halogen-C1-6-alkoxy. Invention also relates to pharmaceutical composition, demonstrating antagonism to receptor V1a, containing effective quantity of formula I compound, and to application of formula I compound for manufacturing medication, possessing antagonistic activity with respect to receptor V1a. |
|
Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport Present invention relates to inhibitors of intestinal apical sodium/phosphate co-transport for treating conditions associated with hyperphosphatemia of formula I: |
|
Invention relates to 1,2,4-triazolone derivatives and pharmaceutically acceptable salts thereof. The disclosed compounds have antagonistic activity with respect to the arginine vasopressin V1b receptor. In formula (IA): R1 is C1-5 alkyl (the C1-5 alkyl is optionally substituted with 1-3 groups selected from a group consisting of hydroxy, halogen atoms, and C3-7 cycloalkyl), C3-7 cycloalkyl or a 4-8-member saturated heterocycle, containing one heteroatom selected from an oxygen atom; R2 is a hydrogen atom; R3 is a phenyl or pyridyl (the phenyl or pyridyl is optionally substituted with 1 or 2 groups selected from a group consisting of C1-5 alkoxy, halogen atoms, cyano and C1-5 alkylsulphonyl); R4 and R5 can be identical or different, and each is a hydrogen atom or C1-5 alkyl (the C1-5 alkyl is optionally substituted with one hydroxy), or R4 and R5 optionally, together with a nitrogen atom with which they are bonded, form a 4-8-member saturated or unsaturated heterocycle, optionally containing one nitrogen, oxygen or sulphur atom, in addition to the nitrogen atom with which they are bonded, in a ring (the 4-8-member saturated or unsaturated heterocycle is optionally substituted with one or two groups selected from a group consisting of hydroxy, C1-5 alkyl ( the C1-5 alkyl is optionally substituted with one hydroxy), C1-5 alkoxy, halogen atoms, cyano, C2-5 alkanoyl, aminocarbonyl, trifluoromethyl and amino (the amino is optionally substituted with one or two groups selected from a group consisting of C1-5 alkyl and C2-5 alkanoyl), and the 4-8-member saturated heterocycle optionally has a C1-5 alkylene group which crosslinks two different carbon atoms in the ring, or form 2-oxa-6-azaspiro[3.3]hept-6-yl or 7-oxa-2-azaspiro[3.5]non-2-yl; A is phenylene, pyridinediyl or pyrimidinediyl (the phenylene, pyridinediyl and pyrimidinediyl are optionally substituted with one group selected from halogen atoms and C1-5 alkoxy); X is a single bond or -O-; Ra is a hydrogen atom or a C1-5 alkyl and n equals 0 or 1. The invention also relates to 1,2,4-triazolone derivatives, the structural formulae and values of radicals of which are given in the claim, to a pharmaceutical composition and to a therapeutic or preventive agent containing a 1,2,4-triazolone derivative or a pharmaceutically acceptable salt thereof. |
|
Invention relates to particles for delivery and a method of treating and/or cleaning an application site. The composition contains: a) an auxiliary ingredient selected from a group, b) a population of particles of microcapsules containing an oil-dispersible or soluble core material and non-anionic wall material at least partially surrounding the core material, wherein the microcapsule wall material contains: a reaction product of a first composition in the presence of a second composition containing an emulsifier which is a non-anionic compound, wherein the first composition contains a reaction product of i) an oil-dispersible or soluble amine acrylate or amine methacrylate with ii) multifunctional acrylate or methacrylate monomer or oligomer and iii) a soluble acid and an initiator, where the soluble acid and amine acrylate are in molar ratio of 3:1 to 1:3 and together make up 0.1-20 wt % of the weight of the wall material, the non-anionic emulsifier contains a water-dispersible or soluble material at pH 4-12 and, optionally, an aqueous phase initiator, wherein the reaction product of the first composition and the second composition lead to the formation of a population of microcapsules having non-anionic microcapsule wall material with low permeability for the core material and characterised by a zeta-potential equal to greater than -5 mV; the obtained microcapsules are characterised by adhesion to anionic surfaces, wherein said composition is a consumer product. |
|
Method of prevention and treatment of vulvovaginitis and vaginitis Invention relates to medicine, namely to obstetrics and gynaecology, and can be used for the sanitation of the mucosa and recovery of vaginal biocenosis in case of non-specific and vulvovaginal candidiasis and vaginoses in gynaecological practice, including the period of pregravidary preparation, in obstetrics - for the correction of vaginal dysbiosis in pregnant women. The method of prevention and treatment of vulvovaginitis and vaginosis, including pregnant women, consists in the following: at the first stage the irrigation of external genitalia with the solution "Malavit" is performed, at the second stage a loose gauze pad, also soaked in the "Malavit" solution, is introduced into the posterior vaginal fornix, with the application of the water "Malavit" solution with 1/20 dilution, with the preliminary application of the "Malavit" cream-gel on a gauze pad at the second stage. The method has 90% efficiency with the recovery of physiological vaginal biocenosis in gynaecological patients and pregnant women with non-specific and vulvovaginal candidiasis, bacterial vaginosis. |
|
|
Preparation for parenteral administration contains a pharmaceutically acceptable salt of methylethyl pyridinol, which additionally contains riboflavin and has a composition, g/100 ml: methylethyl pyridinol hydrochloride or succinate 1.0-5.0; riboflavin 0.002-0.05; water for injections up to 100 ml. |
|
Compositions and methods of modulating smn2 splicing in subject Claimed group of inventions relates to field of medicine. Claimed is method of relieving at least one symptom of spinal muscular atrophy in subject, which includes introduction to subject of antisense compound, containing antisense oligonucleotide, complementary to intron 7 of pre-mRNA, coding human SMN2. Claimed is application of such antisense compound in production of medication for relieving or treatment of at least one symptom of spinal muscular atrophy in subject. |
|
Pharmaceutical composition for prevention or treatment of diabetic peripheral neuropathy, which contains as active ingredient mixed extracts of rhizome of Dioscorea batatas Decaisne, Dioscorea japonica Thunberg, or Dioscorea opposita Thunberg, and rhizome of Dioscorea nipponica in weight ratio 3.5:1 wt/wt and pharmaceutically acceptable carrier. Functional health-improving food product for prevention or improvement of diabetic peripheral neuropathy. |
|
Antioxidant compositions for local application Invention represents cosmetic composition for local application in aerosol container, where composition contains (a) L-ascorbic acid or its pharmaceutically acceptable salt or its ester in amount from 1 wt % to 20 wt %, (b) water in amount from 20 wt % to 60 wt %, (c) lower (C1-C6 alkyl) alcohol, selected from the group, consisting of ethanol, propanol, isopropanol, n-butyl alcohol and tert-butyl alcohol, in amount from 20 wt % to 60 wt %, (d) optionally dermatologically acceptable excipient and (e) aerosol propellent, where composition forms aerosol foam after leaving said container and where all percent values are expressed as percent values relative to weight of final obtained composition, and the total amount constitutes 100 wt %. |
|
Solid dispersions, containing kinase inhibitors Invention represents product in form of solid dispersion, containing N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea or its pharmaceutically acceptable salt, at least, one pharmaceutically acceptable water-soluble polymer carrier and, at least, one pharmaceutically acceptable surface-active substance. |
|
Means for treatment and prevention of sleep disorders Invention relates to means for treatment and prevention of sleep disorders, which represents glycine conjugate, immobilised on particles of detonation nanodiamond with size 2-10 nm, with content of glycine to 21±3 wt %. |
|
Method of production of rusovostatin nanocapsules in sodium alginate Suggested method feature is use of sodium alginate as nanocapsules enclosure, and carbon tetrachloride as precipitant during nanocapsules production by physical and chemical method of precipitation by nonsolvent. |
|
|
Method of nanocapsules production of dorogov's antiseptic-excitor (dae) fraction 2 in chitosan Invention relates to nanotechnology, in particular to method of production of DAE nanocapsules in chitosan. The suggested method feature is use of chitosan as microcapsules enclosure, and carbon tetrachloride as precipitant during microcapsules production by physical and chemical method of precipitation by nonsolvent. |
|
|
Method for producing antioxidant microcapsules exhibiting supramolecular properties Invention refers to pharmaceutical industry, namely to a method for producing antioxidant microcapsules of: vitamins C, E, eleuterococcus or ginseng extract. A method for producing antioxidant microcapsules of: vitamins C, E, eleuterococcus or ginseng extract, wherein a microcapsule coating represents sodium alginate; vitamins C, E, eleuterococcus or ginseng extract is dissolved in dimethylsulphoxide, and the prepared mixture is dispersed into alginate suspension in butanol, stirred; thereafter ethanol and water are added; then the above suspension is filtered and dried in the specific environment. |
|
|
Compositions and methods for stimulating gastrointestinal motor function Invention refers to medicine and aims at treating a temporary deterioration of the gastrointestinal motor function caused by patient's postoperative intestinal obstruction. Administered is a therapeutically effective amount of a peptidyl ghrelin analogue. |
|
Invention relates to field of biotechnology, genetic engineering and virology. In addition to SIN-vector system contains besides first helper plasmid, intended for expression of viral fusion protein gag-pol, and second helper plasmid, intended for expression of envelope protein (env) of retrovirus. First and second helper plasmids, contained in packaging cell line or applied for its short-term transfection, serve for creation of non-replicating (RCR-incompetent) viral particles. Viral particles contain RNA, which contains on 3'-end SIN-LTR, claimed in invention, where RNA can have therapeutically effective segment, which, for instance, represents transgene. For this purpose extensive deletion of U3-region, which in the process of reverse transcription is copied in 5' LTR, is provided in 3'-SIN-LTR. In addition, all coding ASLV regions, as well as retroviral splicing donor sites are removed from SIN-vector. Invention can be applied in genetic therapy. |
|
5-oxypyrimidine derivatives possessing immunomodulatory activity Invention refers to new 2-isopentyl-4,6-dimethyl-5-oxypyrimidine of formula (I) possessing immunomodulatory activity. The compounds can be used in medicine as an immunomodulatory agent for producing preparations used in treating immunodeficient diseases, infectious diseases, after radiation therapy, in various age-related and functional immune response failures. The compound of formula (I) in stimulating the cell immunity causes the pronounced stimulation of various T-lymphocyte subpopulations when administered in the wide range of doses. (I) , wherein R is isopentyl. A method for producing the compound of formula (I) consists in a reaction of isocapronic acid amide in glacial acetic acid with chloroacetyl acetone to produce 2-isopentyl-4-methyl-5-acetyloxazole, which reacts to ammonia solution to produce a target compound. |
|
Method of phototherapy with antioxidant in case of chronic polypoid rhinosinusitis Laser interstitial thermotherapy of a polipoid tissue in the nasal cavity is preliminarily performed with high-energy laser radiation. A day after the said procedure a 1% solution of emoxipine in a volume up to 1.0 ml is introduced into the polyp stroma. After that, the distal end of a flexible light guide of the light diode therapy apparatus "AFS/S", radiating visible blue radiation with a wavelength of 0.45 mcm, power of radiation of 120 mW, light spot diameter up to 2 cm, is brought to the polyp. After that, the 5-minute long illumination of the polyp is carried out, with the repetition of the entire course daily, for 7 days. |
|
Derivative of diphenyl sulphide, and pharmaceutical product containing it as active ingredient Invention relates to derivative of diphenyl sulphide, that can be used in medicine as antagonist of S1P3 receptor of common formula (1) |
|
Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of thereof application Invention relates to selenophene compound of formula (I) or its pharmaceutically acceptable salt. X stands for selenium, Y and Z stand for carbon atoms; or Y stands for selenium, X and Z stand for carbon atoms; or Z stands for selenium, X and Y stand for carbon atoms; A stands for N; B stands for NR5, where R5 is selected from hydrogen, or alkyl; Ar stands for aryl or heteroaryl ring; aryl represents benzene or naphthalene ring, and heteroaryl represents 6-membered aromatic ring, which contains one, two or three nitrogen atoms; or heteroaryl stands for 5-membered aromatic ring, which contains one or several heteroatoms, selected from sulphur, oxygen and nitrogen, on condition that not more than one oxygen or sulphur atom is present; and such rings include pyridine, pyridazine, pyrazine, pyrimidine, thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole and isothiazole; optionally substituted with one, two or several groups, independently selected from hydrogen, halogen, thiol, sulphonamide, C1-6alkyl, secondary C1-6alkyl, tertiary C1-6alkyl, C2-6alkinyl, C1-4alkoxycarbonyl and phenyl; R1, R2 and R3 are independently selected from hydrogen, carboxylic acid, amino, nitro, cyano, sulphonic acid, thiol, trihalomethyl, C1-6alkyl, secondary C1-6alkyl, tertiary C1-6alkyl, C1-4alkoxycarbonyl, aminocarbonyl, C1-6alkylaminocarbonyl, di(C1-6alkyl)aminocarbonyl, and phenyl; or R1 and R2 are bound, and together with atoms, which they are bound to, they form 5-7-membered optionally substituted carbocyclic or perhydroheterocyclic ring, given in invention formula; or R1 and R2 are bound, and together with atoms, which they are bound to, form optionally substituted aryl or non-substituted heteroaryl ring, fused with selenophene; and aryl represents benzene ring, and heteroaryl represents 6-membered aromatic ring, which contains one nitrogen atom. Methods of obtaining selenophene compound (versions), pharmaceutical composition, methods of treatment or inhibition, or control of cell proliferative disorder are also claimed. |
|
Method for integrated treatment of polycystic ovarian syndrome and obesity Integrated treatment of polycystic ovarian syndrome and obesity is ensured by administering Yarina combined oral contraceptive 1 tablet in the morning, metformin 500 mg 2 tablets in the evening; body weight reduction is provided by taking Listata 120 mg 3 times a day with meals; normalising blood glucose and insulin is enabled by prescribing dry milled root artichoke 1.5 gram in the morning and evening 30 minutes before a meal; normalising lipid exchange requires taking Milk Thistle Oil Cakes biologically active food supplement 2.0 gram in the morning and evening 30 minutes before a meal during 3 months. |
|
Invention relates to method of obtaining preparation basing on interaction of cis-dichlorodiamminplatinum (II) with arabinogalactan, which possesses biological activity and can be used as medication in treatment of malignant diseases. Method of obtaining preparation, basing on interaction of cis-dichlorodiamminplatinum (II) salt with arabinogalactan, include heating on water bath for 15 minutes, filtration and planting into alcohol under specified conditions. |
Another patent 2550869.